Bisphosphonate
Mostrando 1-12 de 64 artigos, teses e dissertações.
-
1. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence
ABSTRACT It is now well recognized that over the lifetime of a patient with osteoporosis, more than one medication will be needed to treat the disease and to decrease fracture risk. Though current gaps in osteoporosis therapy can be potentially mitigated with sequential and combination regimens, how to move seamlessly amongst the multiple treatments currentl
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
2. Histomorphometry of Bone Microarchitecture in Rats Treated with Vitamin D and Bisphosphonate in the Management of Osteoporosis
Resumo Objetivo Verificar como a administração conjunta de alendronato de sódio (ALN) e vitamina D3 (VD) atua na microarquitetura óssea em ratas com osteoporose induzida por glicocorticoide. Métodos O experimento utilizou 32 ratas da linhagem Wistar, com peso médio de 300 a 400g, com 90 dias de vida. A indução da osteoporose consistiu na administra
Revista Brasileira de Ortopedia. Publicado em: 2022
-
3. Clinical profile of individuals with bisphosphonate-related osteonecrosis of the jaw: an integrative review
ABSTRACT BACKGROUND: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is still the most prevalent type of osteonecrosis with clinical relevance. In Brazil, bisphosphonate use is high but there is a lack of epidemiological studies on BRONJ. OBJECTIVE: To determine the clinical profile of BRONJ in a Brazilian population through an integrative review
Sao Paulo Med. J.. Publicado em: 2020-08
-
4. Errata – É importante saber onde posicionar o marcador esférico para o planejamento digital de artroplastia de quadril?
ABSTRACT BACKGROUND: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is still the most prevalent type of osteonecrosis with clinical relevance. In Brazil, bisphosphonate use is high but there is a lack of epidemiological studies on BRONJ. OBJECTIVE: To determine the clinical profile of BRONJ in a Brazilian population through an integrative review
Rev. bras. ortop.. Publicado em: 2020-08
-
5. Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?
ABSTRACT Osteoporosis is a systemic skeletal disease characterized by reduced bone mass and deterioration of bone tissue microarchitecture leading to an increased risk of fractures. Fragility fractures, especially hip fractures, are associated with a significant reduction in the physical function and quality of life of affected patients, as well as increased
Arch. Endocrinol. Metab.. Publicado em: 2020-08
-
6. Supporting people with severe mental health conditions during the COVID-19 pandemic: considerations for low- and middle-income countries using telehealth case management
ABSTRACT Osteoporosis is a systemic skeletal disease characterized by reduced bone mass and deterioration of bone tissue microarchitecture leading to an increased risk of fractures. Fragility fractures, especially hip fractures, are associated with a significant reduction in the physical function and quality of life of affected patients, as well as increased
Braz. J. Psychiatry. Publicado em: 2020-08
-
7. The efficacy of sustained-release chitosan microspheres containing recombinant human parathyroid hormone on MRONJ
Abstract Treatment of patients with bisphosphonate usage is a significant concern for oral surgeons because it interferes with jaw bone turnover and regeneration. In case of adverse effects manifesting related to bisphosphonate use, oral surgeons are usually treating and keep the patient’s symptoms under control. In this study, we aimed to investigate a ne
Braz. oral res.. Publicado em: 29/08/2019
-
8. Treatment of bisphosphonate-related osteonecrosis using platelet-rich plasma: microtomographic, microscopic, and immunohistochemical analyses
Abstract The present study aimed to investigate the use of platelet-rich plasma (PRP) on tooth extraction sites in rats treated with bisphosphonates. Thirty Albinus Wistar male rats were administered 0.035 mg/kg zoledronic acid intravenously for 8 weeks, divided into four administrations with a 2-week interval between each application, after which their uppe
Braz. oral res.. Publicado em: 01/07/2019
-
9. Humoral hypercalcemia of pregnancy treated with bisphosphonates
SUMMARY Hypercalcemia can be hazardous during pregnancy, most cases being due to primary hyperparathyroidism. We report a case of hypercalcemia with suppressed PTH levels necessitating treatment with bisphosphonates during pregnancy. A 38-year-old woman at the 26th week gestation was admitted because of symptomatic hypercalcemia. She did not take any medicat
Arch. Endocrinol. Metab.. Publicado em: 2018-02
-
10. Collagen sponge and rhBMP-2 improve socket healing in rats treated with zoledronic acid
Abstract The aim of the present study was to evaluate the possible use of a commercial absorbed collagen sponge and bone morphogenetic protein (BMP) for the prevention of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in rats. Twenty rats received intraperitoneal injections of 0.1-mg/kg of zoledronic acid three times a week for eight weeks before th
Braz. oral res.. Publicado em: 07/12/2017
-
11. Short term sodium alendronate administration improves the peri-implant bone quality in osteoporotic animals
Abstract Sodium alendronate is a bisphosphonate drug that exerts antiresorptive action and is used to treat osteoporosis. Objective The aim of this study was to evaluate the bone repair process at the bone/implant interface of osteoporotic rats treated with sodium alendronate through the analysis of microtomography, real time polymerase chain reactions and
J. Appl. Oral Sci.. Publicado em: 2017-02
-
12. Experimental osteonecrosis: development of a model in rodents administered alendronate
Abstract The main objective of this study was to cause bisphosphonate-related osteonecrosis of the jaws to develop in a rodent model. Adult male Holtzman rats were assigned to one of two experimental groups to receive alendronate (AL; 1 mg/kg/week; n = 6) or saline solution (CTL; n = 6). After 60 days of drug therapy, all animals were subjected to first lowe
Braz. oral res.. Publicado em: 22/08/2016